We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, Chardan reduced its price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) from $16 to $14 while maintaining a Buy rating on the stock. This update comes after the company’s first-quarter 2026 results. Chardan’s analyst told investors in […]
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) just released its latest quarterly report and things are not looking...
Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6%
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Why Iovance Biotherapeutics Stock Is Back on Investors’ Radar Iovance Biotherapeutics (IOVA) is drawing fresh attention after short interest in the stock eased and several large institutions increased positions, hinting at a shift in how the market is approaching the company. This interest arrives alongside a proposal for the June 10, 2026 annual meeting to raise authorized common shares from 500,000,000 to 650,000,000. This is a move that can affect how you think about future financing and...
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Biotherapeutics, listed as NasdaqGM:IOVA, has proposed a significant increase to its authorized common stock. Shareholders are scheduled to vote on the proposal at the company’s upcoming annual meeting. The authorization change would give the company more flexibility for future equity issuances, subject to board approval. Iovance Biotherapeutics focuses on cell therapies targeting cancer, an area that often requires substantial capital for clinical development, manufacturing...
Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?